THYROID FUNCTION TESTS: WHY TSH ALONE IS NEVER THE FULL PICTURE

Thyroid disorders are among the most common endocrine conditions in the world, affecting an estimated 20 million Americans — roughly 60% of whom are undiagnosed. Yet the standard screening protocol for thyroid function in primary care consists of a single test: TSH (thyroid-stimulating hormone). This is the equivalent of evaluating a car's engine by only measuring the signal from the ignition switch, without looking at the fuel delivery, combustion, or exhaust systems that actually do the mechanical work.

TSH is produced by the pituitary gland and signals the thyroid to produce more hormone. It is useful as a first-pass screening tool because it rises when the pituitary detects insufficient circulating thyroid hormone. But TSH tells you nothing about whether the thyroid hormone being produced is converting properly to its active form in peripheral tissues, whether the body is generating an immune attack against the thyroid, or whether circulating thyroid hormone levels are genuinely adequate for cellular function. These are precisely the questions that matter most for people experiencing fatigue, weight changes, depression, hair loss, and cognitive impairment — symptoms that are routinely attributed to thyroid dysfunction and routinely missed by TSH-only testing.

What TSH Actually Measures — and What It Does Not

TSH is a glycoprotein released by the anterior pituitary in a pulsatile, circadian pattern. It operates through a classic negative feedback loop: rising T4 and T3 inhibit TSH release; falling levels stimulate it. The elegance of this system is that a single TSH measurement captures the pituitary's integrated assessment of thyroid hormone adequacy over the preceding hours to days.

The problem is that this feedback loop is calibrated to maintain T4 levels within a reference range — not to guarantee adequate T3 delivery to every tissue. Several scenarios produce a normal TSH with functionally inadequate thyroid activity: poor T4-to-T3 conversion (discussed below), pituitary resistance to thyroid hormone (rare, but documented), selenium deficiency impairing deiodinase enzymes, elevated cortisol from chronic stress suppressing T3 production, and early Hashimoto's thyroiditis in which thyroid hormone levels fluctuate while TSH temporarily compensates.

TSH also varies significantly with timing. It is highest in the early morning (typically between 2-4 AM) and lowest in mid-afternoon, with variation of up to 50-100% across the day. Most blood draws occur mid-morning, which captures TSH near its daily inflection point — another source of interpretive imprecision. TSH also rises significantly in winter months in northern latitudes, an adaptation to increased metabolic demand that the TSH-only approach cannot contextualise.

Free T4 vs Total T4: Why the Bound Fraction Does Not Matter

The thyroid gland produces approximately 100 μg of thyroxine (T4) daily. Roughly 99.97% of this circulates bound to carrier proteins — primarily thyroid-binding globulin (TBG), transthyretin, and albumin. Only the unbound 0.03% — Free T4 — is biologically available to enter cells and undergo conversion to T3. Total T4 measures the entire pool (bound plus free) and is therefore heavily influenced by changes in TBG levels.

Oestrogen increases TBG production significantly — which is why oral contraceptives, HRT, and pregnancy can substantially elevate Total T4 without any change in actual thyroid hormone availability. Measuring Free T4 eliminates this confound. Reference ranges for Free T4 typically span 0.8-1.8 ng/dL (10-23 pmol/L depending on the assay). Functional medicine targets the upper half of this range — approximately 1.2-1.8 ng/dL — reflecting evidence that Free T4 in the lower portion of the reference range is associated with subclinical hypothyroid symptoms.

Free T3: The Metabolically Active Hormone Your Panel Is Missing

Triiodothyronine (T3) is the biologically active thyroid hormone. It binds to thyroid hormone receptors in the nucleus of virtually every cell in the body, regulating the transcription of thousands of genes involved in metabolic rate, thermogenesis, cardiac contractility, gastrointestinal motility, mood neurotransmitter synthesis, and mitochondrial biogenesis. The metabolic significance of T3 versus T4 can be understood by the fact that T3 binds thyroid hormone receptors with approximately 10-15 times greater affinity than T4.

The thyroid gland secretes some T3 directly, but approximately 80% of circulating T3 is derived from peripheral deiodination of T4 — primarily in the liver (by type 1 deiodinase, D1) and in target tissues including the brain and heart (by type 2 deiodinase, D2). This conversion step is the critical bottleneck that TSH-only testing completely ignores.

Free T3 reference ranges typically span 2.3-4.2 pg/mL (3.5-6.5 pmol/L). The functional optimal is considered to be in the upper third of the reference range — approximately 3.4-4.2 pg/mL. Free T3 in the lower half of the reference range, particularly when accompanied by classic hypothyroid symptoms, should be taken seriously regardless of where TSH sits. Studies in patients on levothyroxine (T4-only) replacement show that a significant minority remain symptomatic with normal TSH because peripheral T3 production is insufficient — a problem that can only be detected by measuring Free T3 directly.

Reverse T3: When Your Body Shunts Thyroid Hormone Down the Wrong Pathway

T4 can be deiodinated in two ways: removal of the outer ring iodine produces active Free T3, while removal of the inner ring iodine produces Reverse T3 (rT3) — a biologically inactive isomer that competitively binds thyroid hormone receptors, blocking active T3 without exerting any metabolic effect. The body deliberately shifts T4 conversion toward rT3 in certain physiological states, most notably during acute illness or starvation, as a conservation mechanism to reduce metabolic rate and preserve glucose.

The problem arises when rT3 production becomes chronically elevated in non-starvation conditions. Elevated cortisol — from chronic psychological stress, sleep deprivation, HPA axis dysregulation, or exogenous glucocorticoid use — strongly promotes rT3 production and inhibits D1 deiodinase activity. So does severe caloric restriction, systemic inflammation, heavy metal toxicity, and selenium deficiency. The clinical result is a pattern sometimes called "functional hypothyroidism" or "low T3 syndrome": TSH within range, T4 within range, but Free T3 low and rT3 elevated, with full symptomatic hypothyroidism.

Reference ranges for Reverse T3 vary by lab but are typically 9-25 ng/dL. Elevated rT3 (above 20 ng/dL) in the context of low Free T3 and hypothyroid symptoms is clinically meaningful. Some practitioners use the Free T3-to-Reverse T3 ratio (optimal above 20 when T3 is in pg/mL and rT3 is in ng/dL) as a composite marker of thyroid hormone adequacy at the tissue level.

Hashimoto's Thyroiditis: The Autoimmune Cause That Standard Testing Misses

Hashimoto's thyroiditis is an autoimmune condition in which the immune system generates antibodies against thyroid tissue — primarily against thyroid peroxidase (TPO), the enzyme responsible for iodine organification during thyroid hormone synthesis, and against thyroglobulin (Tg), the protein backbone from which thyroid hormones are cleaved. Hashimoto's is the most common cause of hypothyroidism in iodine-sufficient countries, affecting roughly 5% of the population and up to 10% of women over 40.

The critical point is that Hashimoto's can be present — and causing symptoms — for years before TSH rises out of the reference range. During the early stages of the disease, the autoimmune destruction of thyroid tissue may cause transient leakage of stored thyroid hormone, producing periods of hyperthyroid symptoms (palpitations, anxiety, heat intolerance, insomnia) alternating with periods of hypothyroidism. Through all of this, TSH may appear completely normal.

Anti-TPO antibodies are positive in approximately 95% of Hashimoto's cases; anti-thyroglobulin antibodies are positive in about 60-80% of cases, including around 30% where anti-TPO is negative. Ordering both antibody tests is therefore important for ruling out Hashimoto's comprehensively. Reference ranges typically flag anti-TPO above 34 IU/mL and anti-Tg above 40 IU/mL as abnormal, but even mildly elevated titres in the presence of compatible symptoms and a characteristic ultrasound pattern (heterogeneous, hypoechoic gland) are diagnostically significant.

Subclinical Hypothyroidism: The Grey Zone That Is Not Actually Grey

Subclinical hypothyroidism is defined as elevated TSH with normal Free T4 — and affects approximately 4-10% of the general population, rising to 20% in women over 60. The conventional view in primary care is that subclinical hypothyroidism with TSH below 10 mIU/L is not worth treating in the absence of symptoms or pregnancy. The evidence does not support this complacency.

Multiple meta-analyses have found that subclinical hypothyroidism is associated with significantly elevated LDL cholesterol, impaired endothelial function, increased carotid intima-media thickness (a marker of atherosclerosis), higher rates of depression, and in some population studies, increased cardiovascular mortality. The Thyroid Studies Collaboration (2010, n=55,287) found that TSH of 10 mIU/L or higher was associated with a 20% increase in coronary heart disease events.

The decision to treat subclinical hypothyroidism with levothyroxine is genuinely individualised — age, TSH level, antibody status, symptom burden, and cardiovascular risk all factor in. But the decision can only be made correctly if the full panel has been measured. Relying on TSH alone forecloses the clinical conversation entirely.

How to Request a Full Thyroid Panel and Interpret the Results

A complete thyroid assessment includes: TSH, Free T4, Free T3, Reverse T3, anti-TPO antibodies, and anti-thyroglobulin antibodies. This panel can be requested from a GP with clinical justification, ordered through a functional medicine or endocrinology referral, or accessed directly through private lab services. Blood should be drawn in the morning (when TSH is at its daily peak) and ideally fasting.

For patients already on levothyroxine, the Free T3 and Reverse T3 are particularly critical — they reveal whether conversion from the prescribed T4 is adequate. Research consistently shows that approximately 10-15% of patients on T4 monotherapy do not convert sufficiently and may benefit from combination T4/T3 therapy or a switch to desiccated thyroid extract (which contains both T4 and T3 in physiological ratios).

When Hashimoto's is confirmed, management extends beyond thyroid hormone optimisation to include immune modulation: selenium supplementation (200 μg/day selenomethionine has been shown in multiple RCTs to reduce TPO antibody titres by 20-40%), vitamin D optimisation (target 50-80 ng/mL), gluten elimination in coeliac-positive or coeliac-antibody-positive patients, and stress management (cortisol is a direct trigger for Hashimoto's flares via Th1/Th2 imbalance mechanisms).